For their study, researchers from Memorial Sloan-Kettering Cancer Center in New York City administered a single dose of clindamycin to a group of mice. Results showed the mice experienced weight loss, diarrhea and colitis and a 40-50 percent higher mortality rate. In addition, surviving mice remained susceptible to C. difficile infection for at least 28 days.
Related Articles on C. Difficile:
Varying Antibiotics Equally Effective in Treating Clostridium Difficile Infections
Researchers Discover Possible Defense Against C. Difficile
Two California Hospitals Report C. Diff Outbreaks
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
